pediatrics
TNF Receptor–Associated Periodic Syndrome (TRAPS)
Treatment of TRAPS
Corticosteroids Anakinraandcanakinumab Short-term nonsteroidal anti-inflammatory drugs may be used for mild attacks. However, inflammatory attacks usually require corticosteroids (eg,prednisone). The dosage of corticosteroids may need to be increased over time and this therapy may, over time, paradoxically lead to more prolonged flare-ups. once a day ( Treatment references , 1.ter Haar NM, Oswald M, Jeyaratnam J, et al: Recommendations for the management of autoinflammatory diseases.Ann Rheum Dis74(9):1636–1644, 2015. doi: 10.1136/annrheumdis-2015-207546 2.Gattorno M, Pelagatti MA, Meini A, et al: Persistent efficacy ofanakinrain patients with tumor necrosis factor receptor-associated periodic syndrome.Arthritis Rheum58:1516–1520, 2008. doi: 10.1002/art.23475 3.Gattorno M, Obici L, Cattalini M, et al:Canakinumabtreatment for patients with active recurrent or chronic TNF receptor-associated periodic syndrome (TRAPS): An open-label, phase II study.Ann Rheum Dis76(1):173–178, 2016. doi: 10.1136/annrheumdis-2015-209031 4.De Benedetti F, Gattorno M, Anton J, et al:Canakinumabfor the treatment of autoinflammatory recurrent fever syndromes.N Engl J Med378(20):1908–1919, 2018. doi: 10.1056/NEJMoa1706314 5.Drewe E, McDermott EM, Powell PT, et al: Prospective study of anti-tumour necrosis factor receptor superfamily 1B fusion protein, and case study of anti-tumour necrosis factor receptor superfamily 1A fusion protein, in tumour necrosis factor receptor associated periodic syndrome (TRAPS): Clinical and laboratory findings in a series of seven patients.Rheumatology42:235–239, 2003. doi: 10.1093/rheumatology/keg070 6.Quillinan N, Mannion G, Mohammad A, et al: Failure of sustained response toetanerceptand refractoriness toanakinrain patients with T50M TNF-receptor-associated periodic syndrome.Ann Rheum Dis70(9):1692–1693, 2011. doi: 10.1136/ard.2010.144279 